The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients
Open accessAbstract
Summary: The potent anti-tumour activities of γδ T cells have prompted the development of protocols in which γδ-agonists are administered to cancer patients. Encouraging results from small Phase I trials have fuelled efforts to characterize more clearly the application of this approach to unmet clinical needs such as metastatic carcinoma. To examine this approach in breast cancer, a Phase I trial was conducted in which zoledronate, a Vγ9Vδ2 T cell agonist, plus low-dose interleukin (IL)-2 were administered to 10 therapeutically terminal, advanced metastatic breast cancer patients. Treatment was well tolerated and promoted the effector maturation of Vγ9Vδ2 T cells in all patients. However, a statistically significant correlation of clinical outcome with peripheral Vγ9Vδ2 T cell numbers emerged, as seven patients who failed to sustain Vγ9Vδ2 T cells showed progressive clinical deterioration, while three patients who sustained robust peripheral Vγ9Vδ2 cell populations showed declining CA15-3 levels and displayed one instance of partial remission and two of stable disease, respectively. In the context of an earlier trial in prostate cancer, these data emphasize the strong linkage of Vγ9Vδ2 T cell status to reduced carcinoma progression, and suggest that zoledronate plus low-dose IL-2 offers a novel, safe and feasible approach to enhance this in a subset of treatment-refractory patients with advanced breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
(2001) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/j.1447-0756.2001.tb01222.x · Cited by 3,461
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135
Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806285 · Cited by 1,025
Natural and synthetic non-peptide antigens recognized by human γδ T cells
Tanaka, Y., Morita, C. T., Tanaka, Y., Nieves, E., Brenner, M. B., & Bloom, B. R. (1995) · Nature · doi:10.1038/375155a0 · Cited by 1,013
Smyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870
Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells
Gober, H.-J., Kistowska, M., Angman, L., Jenö, P., Mori, L., & De Libero, G. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021500 · Cited by 847
Adoptive immunotherapy for cancer: building on success
Gattinoni, L., Powell, D. J., Rosenberg, S. A., & Restifo, N. P. (2006) · Nature Reviews Immunology · doi:10.1038/nri1842 · Cited by 845
Stimulation of Human γδ T Cells by Nonpeptidic Mycobacterial Ligands
Constant, P., Davodeau, F., Peyrat, M.-A., Poquet, Y., Puzo, G., Bonneville, M., & Fournié, J.-J. (1994) · Science · doi:10.1126/science.8146660 · Cited by 711
Immunotherapy and chemotherapy — a practical partnership
Lake, R. A., & Robinson, B. W. S. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1613 · Cited by 646
γδ T cells for immune therapy of patients with lymphoid malignancies
Wilhelm, M., Kunzmann, V., Eckstein, S., Reimer, P., Weissinger, F., Ruediger, T., & Tony, H.-P. (2003) · Blood · doi:10.1182/blood-2002-12-3665 · Cited by 550
Dieli, F., Vermijlen, D., Fulfaro, F., Caccamo, N., Meraviglia, S., Cicero, G., Roberts, A., Buccheri, S., D'Asaro, M., Gebbia, N., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0199 · Cited by 497
Self-citationγδ T Cells and the Lymphoid Stress-Surveillance Response
Hayday, A. C. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.006 · Cited by 495
Self-citationγδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity
Gao, Y., Yang, W., Pan, M., Scully, E., Girardi, M., Augenlicht, L. H., Craft, J., & Yin, Z. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030584 · Cited by 453
MICA Engagement by Human Vγ2Vδ2 T Cells Enhances Their Antigen-Dependent Effector Function
Das, H., Groh, V., Kuijl, C., Sugita, M., Morita, C. T., Spies, T., & Bukowski, J. F. (2001) · Immunity · doi:10.1016/s1074-7613(01)00168-6 · Cited by 409
Peng, G., Wang, H. Y., Peng, W., Kiniwa, Y., Seo, K. H., & Wang, R.-F. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.020 · Cited by 408
Microbial isoprenoid biosynthesis and human γδ T cell activation
Eberl, M., Hintz, M., Reichenberg, A., Kollas, A.-K., Wiesner, J., & Jomaa, H. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00483-6 · Cited by 336
Self-citationDieli, F., Poccia, F., Lipp, M., Sireci, G., Caccamo, N., Di Sano, C., & Salerno, A. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030235 · Cited by 322
Self-citationScotet, E., Martinez, L. O., Grant, E., Barbaras, R., Jenö, P., Guiraud, M., Monsarrat, B., Saulquin, X., Maillet, S., Estève, J.-P., et al. (2005) · Immunity · doi:10.1016/j.immuni.2004.11.012 · Cited by 298
Roelofs, A. J., Jauhiainen, M., Mönkkönen, H., Rogers, M. J., Mönkkönen, J., & Thompson, K. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07435.x · Cited by 289
Cross-presenting human γδ T cells induce robust CD8 + αβ T cell responses
Brandes, M., Willimann, K., Bioley, G., Lévy, N., Eberl, M., Luo, M., Tampé, R., Lévy, F., Romero, P., & Moser, B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810059106 · Cited by 277
Self-citationPerspectives of γδ T Cells in Tumor Immunology
Kabelitz, D., Wesch, D., & He, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3069 · Cited by 251
Bennouna, J., Bompas, E., Neidhardt, E. M., Rolland, F., Philip, I., Galéa, C., Salot, S., Saiagh, S., Audrain, M., Rimbert, M., et al. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0491-8 · Cited by 249
Feldman, E. J., Brandwein, J., Stone, R., Kalaycio, M., Moore, J., O'Connor, J., Wedel, N., Roboz, G. J., Miller, C., Chopra, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.133 · Cited by 249
Kobayashi, H., Tanaka, Y., Yagi, J., Osaka, Y., Nakazawa, H., Uchiyama, T., Minato, N., & Toma, H. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0199-6 · Cited by 237
Engineering lymphocyte subsets: tools, trials and tribulations
June, C. H., Blazar, B. R., & Riley, J. L. (2009) · Nature Reviews Immunology · doi:10.1038/nri2635 · Cited by 204
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim, A., Scher, N. S., Williams, G., Sridhara, R., Li, N., Chen, G., Leighton, J. C., Booth, B. P., Gobburu, J. V. S., Rahman, A., et al. (2003) · PubMed · Cited by 196
Abe, Y., Muto, M., Nieda, M., Nakagawa, Y., Nicol, A., Kaneko, T., Goto, S., Yokokawa, K., & Suzuki, K. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.04.008 · Cited by 176
Antigen recognition by human γδ T cells: pattern recognition by the adaptive immune system
Morita, C. T., Mariuzza, R. A., & Brenner, M. B. (2000) · Springer Seminars in Immunopathology · doi:10.1007/s002810000042 · Cited by 165
Vermijlen, D., Ellis, P., Langford, C., Klein, A., Engel, R., Willimann, K., Jomaa, H., Hayday, A., & Eberl, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4304 · Cited by 159
Self-citationHornychová, H., Melichar, B., Tomšová, M., Mergancová, J., Urminská, H., & Ryška, A. (2008) · Cancer Investigation · doi:10.1080/07357900802098165 · Cited by 113
Major, P. P., & Cook, R. J. (2002) · American Journal of Clinical Oncology · doi:10.1097/00000421-200212001-00003 · Cited by 93
Simoni, D., Gebbia, N., Invidiata, F. P., Eleopra, M., Marchetti, P., Rondanin, R., Baruchello, R., Provera, S., Marchioro, C., Tolomeo, M., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801003y · Cited by 72
Self-citationMajor, P. P. (2002) · The Oncologist · doi:10.1634/theoncologist.7-6-481 · Cited by 66
Mitrofan, L. M., Pelkonen, J., & Mönkkönen, J. (2009) · Bone · doi:10.1016/j.bone.2009.08.010 · Cited by 61
Catellani, S., Poggi, A. D., Bruzzone, A., Dadati, P., Ravetti, J. L., Gobbi, M., & Zocchi, M. R. (2006) · Blood · doi:10.1182/blood-2006-06-028985 · Cited by 59
Mattarollo, S. R., Kenna, T., Nieda, M., & Nicol, A. J. (2006) · International Journal of Cancer · doi:10.1002/ijc.22019 · Cited by 48
Landmeier, S., Altvater, B., Pscherer, S., Juergens, H., Varnholt, L., Hansmeier, A., Bollard, C. M., Moosmann, A., Bisping, G., & Rössig, C. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31819b7c30 · Cited by 39
Reeder, J. G., & Vogel, V. G. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.n.047 · Cited by 23
Tan, P., & Lota, A. S. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.15.2639 · Cited by 10
Cited by
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
Tumor-infiltrating lymphocytes in the immunotherapy era
Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00565-9 · Cited by 880
The interplay between cell signalling and the mevalonate pathway in cancer
Mullen, P. J., Yu, R., Longo, J., Archer, M. C., & Penn, L. Z. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.76 · Cited by 699
Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
Sebestyen, Z., Prinz, I., Déchanet-Merville, J., Silva-Santos, B., & Kuball, J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0038-z · Cited by 425
Cholesterol metabolism: New functions and therapeutic approaches in cancer
Xu, H., Zhou, S., Tang, Q., Xia, H., & Bi, F. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188394 · Cited by 365
Metadata
- Authors
- Meraviglia, S., Eberl, M., Vermijlen, D., Todaro, M., Buccheri, S., Cicero, G., La Mendola, C., Guggino, G., D'Asaro, M., Orlando, V, Scarpa, F., Roberts, A., Caccamo, N., Stassi, G., Dieli, F., & Hayday, A. C.
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-05-10
- Volume
- 161
- Issue
- 2
- Pages
- 290-297
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W2114630456
- Cited by
- 295
- References
- 43
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.